Currently out of the existing stock ratings of Donald Ellis, 32 are a BUY (94.12%), 2 are a HOLD (5.88%).

Donald Ellis

Work Performance Price Targets & Ratings Chart

Analyst Donald Ellis, currently employed carries an average stock price target met ratio of 50.63% that have a potential upside of 80.73% achieved within 360 days. Previously, Donald Ellis worked at JMP.

Donald Ellis’s has documented 67 price targets and ratings displayed on 8 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CLSD, Clearside Biomedical at 21-Dec-2021.

Wall Street Analyst Donald Ellis

Analyst best performing recommendations are on ACRS (ACLARIS THERAPEUTICS).
The best stock recommendation documented was for CLSD (CLEARSIDE BIOMEDICAL) at 10/24/2019. The price target of $4 was fulfilled within 448 days with a profit of $3.08 (334.78%) receiving and performance score of 7.47.

Average potential price target upside

of $17.37 (45.08%) on PCRX (PACIRA PHARMACEUTICALS).
of $10.37 (22%) on AERI (AERIE PHARMACEUTICALS .).
of $8.93 (43.95%) on HZNP (HORIZON PHARMA PLC).

ACRS Aclaris Therapeutics AERI Aerie Pharmaceuticals . ENDP Endo International PLC HZNP Horizon Pharma PLC CLSD Clearside Biomedical OCUL Ocular Therapeutix PCRX Pacira Pharmaceuticals SLGL Sol Gel Technologies Ltd

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Raghuram Selvaraju (HC WAINWRIGHT)